Business Context and Reporting Period
This Form 6-K filing by Xiaobai Maimai Inc. (referred to as Akso Health Group in metadata) covers the month of September 2021. The report details the closing of a private placement transaction previously disclosed in filings dated August 12, 2021, and September 13, 2021.
Key Financial Metrics
The filing focuses on a capital raise event rather than operational financial performance. Key metrics related to the transaction include:
- Total Proceeds: Approximately $10.02 million.
- Units Issued: 6,340,000 units.
- Price per Unit: $1.58.
- Unit Composition: Each unit consists of three ordinary shares and one warrant to purchase three shares.
- Warrant Exercise Price: $3.00 per share.
The filing text does not provide clear values for revenue, profit, cash flow, operating margins, existing debt levels, or general liquidity metrics outside of the proceeds from this specific offering.
Material Changes
The primary material change is the consummation of the private placement on September 17, 2021. This resulted in the issuance of 6,340,000 units to "non-U.S. Persons" pursuant to Regulation S of the Securities Act of 1933. The transaction was executed under a Securities Purchase Agreement (SPA) originally entered into on August 9, 2021, and amended on September 8, 2021.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of specific risks and contingencies beyond the standard regulatory disclosures regarding the private placement structure. The document confirms that all closing conditions of the SPA were satisfied as of September 17, 2021.
Investor Verification Checklist
- Verify the final settlement of the $10.02 million proceeds and their intended use.
- Confirm the updated share count and dilution impact resulting from the issuance of 19,020,000 ordinary shares (6,340,000 units x 3 shares).
- Review the terms of the warrants issued (19,020,000 warrants) and their potential future dilution at the $3.00 exercise price.
- Check subsequent filings for any operational updates or financial results following this capital raise.